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Since the terms ‘hypertension’ and ‘microalbuminuria’ were
first defined, data from numerous studies have documented
the continuous, rather than dichotomous, relation between
blood pressure, albumin excretion, and cardiovascular
disease. Lower blood pressures, down to at least 115/
75 mmHg, and lower albumin excretions, below an estimated
2 mg/day, are associated with less cardiovascular risk. We
hypothesize that the abundances of modern civilization
superimposed on the Paleolithic genotype of humans, which
has not substantially changed in the last 10 000 years, have
considerably shifted the ‘normal’ values for blood pressure
and various biochemical indices such as albuminuria still
found in today’s stone-aged cultures to the ‘neo-normal’
values observed today in the rest of the modern world.
Defining a large portion of the population as ‘normal’ based
upon these dichotomous ‘neo-normal’ standards is not
supported by the data, and therefore seems unjustifiable. We
propose that the medical community consider abandoning
the terms ‘hypertension’ and ‘microalbuminuria’ in favor
of ‘blood pressure-associated’ and ‘albuminuria-associated’
disease.
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WHAT IS NORMAL?
The terms ‘hypertension’ and ‘microalbuminuria’ imply a
threshold level for blood pressure and albuminuria below
which disease risk is not seen. This terminology defines a
large group of people as normal, and ignores the impact that
even minor variations of blood pressure and albumin
excretion may have on disease within the so-called normal
range. In this article, we propose that the medical community
consider abandoning these terms, discuss blood pressure-
and albuminuria-related disease risk, and review treatment
targets for associated cardiovascular and renal protection.
HISTORY
History of hypertension and the joint national committee
Following the first measurement of blood pressure in the
femoral artery of a horse by Hales in 1733, and the
recognition by Bright in 1827 that arteriosclerosis, shrunken
and fibrotic kidneys, and cardiac hypertrophy were clinically
linked, elevated blood pressure as a distinct entity was initially
championed by T Clifford Allbutt in 1893, who was also the
first to use the word ‘hyperpiesia’, or hypertension. Early
pharmaceuticals were first used to treat malignant hyper-
tension in the 1940s and 1950s, with significant improvements
in outcomes. However, whether ‘essential’ hypertension
(a term coined by Janeway in 1904) was a benign condition
or one that would benefit from treatment was not answered
until the VA Cooperative Studies published in 1967 and 1970.
Subsequently, the National High Blood Pressure Educa-
tion Program, developed in 1972 by the National Heart,
Lung, and Blood Institute, published the very first report of
the Joint National Committee on Detection, Evaluation, and
Treatment of High Blood Pressure (JNC 1) in 1977.1 This
report, whose bibliography included solely the VA study
published seven years earlier, recommended intervention in
patients with diastolic blood pressures (DBPs) greater than or
equal to 90 mmHg; DBP4104 mmHg warranted drug
therapy, whereas DBP 90–104 mmHg could initially be
approached with risk factor reduction. Although the 1980
guidelines (JNC 2) defined mild, moderate, and severe
hypertension along the same cutoffs of DBP, JNC 3 in 1984
included systolic blood pressure (SBP) (‘normal’ SBP being
o140 mmHg) in the definition.2,3 Subsequent JNC guide-
lines in 1988, 1993, and 1997 adhered to the same definition
of ‘normal’ blood pressure, with the recognition by JNC 5 of
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a ‘high normal’ category, and by JNC 6 of an ‘optimal’
category within the normal range.4–6
The seventh report of the JNC recognized the associations
between even small increments above 115/75 mmHg with
cardiovascular outcomes, retreating somewhat from older
definitions by reclassifying the ‘high normal’ group as
‘prehypertension’ instead.7 Based upon the fourth National
Health and Nutrition Examination Survey (1999–2000
NHANES), an estimated 58% – the majority of all adults in
the United States – have abnormal blood pressure as defined by
JNC 7 categories of prehypertension or hypertension.8 Given the
continuous association between blood pressure and risk as well
as the absence of the J-curve, future progressive redefining of
normality is all but assured, thus making the term ‘hyper-
tension’ – a term which implies dichotomy – seem unjustifiable.
History of microalbuminuria
The term ‘microalbuminuria’ first appeared in the medical
literature in 1981, used by Viberti and colleagues and
Svendsen and colleagues to describe the presence of
albuminuria below the detection limit of a standard dipstick,
but at a level that was highly predictive of future overt
proteinuria in diabetic patients.9–11 Microalbuminuria became
an official part of the medical lexicon in 1985, defined as an
albumin excretion rate between 20 and 200mg/min. Although
the lower bound was chosen because 95% of ‘normal’
individuals had excretion rates below that limit, it was
recognized that risk of progression to nephropathy was
elevated among diabetics in the ‘high normal’ range.12 Similar
to the relationship between blood pressure and risk of
cardiovascular events, mounting evidence indicates a con-
tinuous relationship between albumin excretion and risk. And
like blood pressure, the concept of a threshold level to define
normality is inconsistent with epidemiological data.
HYPOTHESIS
‘Normal’ from the vantage point of primitive vs modern
anthropomorphism
The anthropologic record indicates that before the last 5000
to 10 000 years, Homo sapiens was considerably smaller in
stature and body weight,13 and presumably characterized by
lower blood pressure, glomerular filtration rate, and
cholesterol than are commonplace today. Stone-age tribes
studied today confirm the anthropomorphic and biochemical
patterns predicted for earlier humans.14–24 At the start of the
Holocene 10 000 years ago, the earth’s climate warmed,
allowing people to establish villages and invent the basic tools
of agriculture, herding, and metallurgy. Humans began to
grow considerably in stature and body mass, and our ‘paleo-
normal’ physiologic values, perhaps lower than 90 mmHg for
SBP, 100 mg/dl for total serum cholesterol, increased
substantially to our current ‘neo-normal’ base of refer-
ence.14,16,18,20–23 Neo-normal values can then be regarded as
excessive to our paleophysiological and genetic heritage;
hence, the benefit in risk reduction seen with therapies that
return values closer to our original set points.
The general concept that our genetic heritage has been greatly
outpaced by our modern environment, thus leading to increased
weight, blood pressure, insulin resistance, and other medical
problems, is forwarded by the ‘thrifty-genotype’ hypothesis.25
‘Thrifty’ genes, which predispose us to low metabolic rates
and salt conservation, evolved to preserve energy and blood
pressure in Paleolithic humans faced with shortages in
energy, salt, and with high physical demands.26 Now faced with
an abundance of food and sedentary lifestyles in modern
humans, these thrifty genes have become associated with disease.
Isolated or ‘primitive’ cultures may arguably be the nearest
representation of ‘normal’ human reference populations with
respect to our genetic heritage. Many such populations have
been identified, whose average blood pressures and cholesterol
levels are very low, accompanied by low rates of cardio-
vascular disease.27 Furthermore, blood pressure and serum
cholesterol values do not increase with age as is commonly
observed outside these isolated cultures. Regardless of the
explanation for such phenomena, whether it be low salt
consumption28 or high intake of cocoa,29 free-living people
with average lifetime blood pressures of 90/60 mmHg are not
hypotensive, but rather healthy and free from the cardio-
vascular morbidity and mortality so prevalent elsewhere.
Thus, from the vantage point of primitive anthropomor-
phism, almost every adult in the United States and indeed
most of the world has abnormally high blood pressure.
MISCONCEPTIONS
The cholesterol example
The National Cholesterol Education Program does not define a
cutoff value for ‘hypercholesterolemia’.30 Rather, the evidence-
based guidelines for the prevention of cholesterol-associated
disease include individualized treatment goals. For example,
the treatment goal for a diabetic is different than the goal
serum cholesterol level for someone with no cardiovascular
risk factors. Furthermore, results from current and future trials
will likely lead to adjusted guidelines and lower targets.
Epidemiologic evidence supports a continuous log-linear
relationship between total serum cholesterol, low-density
lipoprotein (LDL) cholesterol, and the risk of coronary heart
disease in the general population.31,32 The continuous
relationship persists down to an LDL as low as 40 mg/dl,
with every 30 mg/dl higher LDL associated with a 30%
increase in the relative risk of coronary heart disease.31 Newer
randomized trials similarly support the notion that lower is
better. Data from the Heart Protection Study showed that all
subgroups of high-risk individuals, including those whose
starting pretrial LDL was o100 mg/dl, benefited from LDL-
lowering therapy.33 These results were echoed by the PROVE IT
study (Pravastatin or Atorvastatin Evaluation and Infection
– Thrombolysis in Myocardial Infarction 22) in which a
significantly lower risk of death or cardiovascular morbidity
was obtained in high-risk patients with an achieved LDL of
62 mg/dl compared to 95 mg/dl.34
Strikingly similar scenarios exist for blood pressure and
albuminuria, as will be discussed. Taking a page from the
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cholesterol playbook, the appropriate approach to blood
pressure and urinary albumin excretion would be abandon-
ment of ‘hypertension’ and ‘microalbuminuria’, and adoption
of evidence-based treatment goals.
Blood pressure-associated disease
Blood pressure and blood pressure-associated disease should
replace ‘hypertension’ in our lexicon. As pointed out by
Rose,35 and subsequently quoted by MacMahon et al.,36 high
blood pressure can be operationally defined as the level at
which further reductions do not lead to additional benefits.
Treatment targets thus may differ among different comorbid
groups, and targets are likely to change with future
randomized trials of more intensive blood pressure lowering.
The misconception of the J-curve
In 1978, Anderson reported that re-examination of the
Framingham Cohort unsmoothed blood pressure data
revealed no additional benefits to DBPo90 mmHg vis-a-vis
cardiovascular disease.37 A year later, Stewart38 proposed the
concept of the J-curve, and this was followed by confirmation
of the J-curve for DBP in participants of several blood
pressure-lowering trials.39–42 Arguments against the J-curve
hold that the increase in events at the lower end of the
spectrum are, in fact, a result of reverse causality, in that
coexistent comorbid disease such as congestive heart failure
or vascular disease is responsible for both the higher risk of
events and lower SBP or DBP.
Indeed, a 2004 examination of Framingham data impli-
cates pre-existing cardiovascular disease as an explanation of
higher risk at lower DBPs. The authors reported that the risk
of cardiovascular events at DBPo90 mmHg was higher
only among those with SBP4140 mmHg, suggesting that the
J-curve for DBP may be explained by a widened pulse pressure
and high SBP; when SBP was o140 mmHg, lower DBP
decreased the risk of cardiovascular disease.43 Moreover, many
other trials have failed to show a J-curve,44–46 whereas others
demonstrating a J-curve could not fully account for baseline
comorbidity such as the severity of pre-existing heart failure
and vascular disease.41,42 Finally, in an analysis that combined
individual data from almost one million participants with no
baseline cardiovascular disease from 61 prospective studies,
there was a linear association between both SBP and DBP and
risk of cardiovascular mortality down to 115 mmHg SBP and
75 mmHg DBP. At blood pressures below these values, the risk
of cardiovascular mortality was even lower.47
The misconception of ‘normotension’
The linear relationship between blood pressure and cardio-
vascular death just mentioned is reminiscent of the association
between cholesterol and risk of coronary heart disease. Down
to a blood pressure of 115/75 mmHg, every 10 mmHg lower
usual systolic or 5 mmHg lower usual diastolic pressure is
associated during long-term follow-up with a 40% reduction
in risk of death from stroke and a 30% reduction in risk
of death from ischemic heart disease.47 These findings are
consistent with other observational studies,48 and once again
argues that our current definition of normal be re-evaluated.
Results from randomized controlled trials have confirmed
that a further reduction in blood pressure among ‘normo-
tensive’ individuals indeed lowers the risk of cardiovascular
events (Table 1). These studies include populations where the
Table 1 | Randomized trials of blood pressure reduction involving high-risk ‘normotensive’ individuals
Study
Population
(normotensive
subset)
Entry BP (mmHg)
(normotensive
subset) Intervention
BP reduction
(mm/Hg) Outcome
Risk reduction
(normotensive
subset) (%)
HOPE Known vascular
disease or diabetes
plus one other
CV risk factor
n=4942
Not given
(presumed
o140/90)
Ramipril 3/2 (study visits)
10/4 (24 ABPM)
Composite of CV death,
nonfatal stroke, nonfatal
MI
20
PROGRESSa Prior stroke or TIA
n=3189
136/79 Perindopril or
Perindopril plus
indapamide
5/3 (single drug)
12/5 (combination)
Recurrent stroke
Composite of CV death,
nonfatal stroke, nonfatal
MI
27
24
EUROPAa Known CAD
n=8906
Not given
(mean for entire
cohort 137/82)
Perindopril 5/2 Composite of CV death,
nonfatal MI, cardiac arrest
20
CAMELOTa Angiographically
confirmed CAD
n=1991
129/78 Amlodipine or
Enalapril
5/2.5 Composite of CV death,
MI, stroke, TIA, PVD, CHF,
ACS, cardiac arrest
31 (amlodipine)
19 (enalapril, NS)
ABCD Type II DM
n=480
136/84 Nisoldipine or
Enalapril
9/6 Stroke 70
ABCD=Appropriate Blood pressure Control in Diabetes; ABPM=24 h ambulatory blood pressure monitoring; ACS=acute coronary syndrome; CAD=coronary artery disease;
CAMELOT=Comparison of Amlodipine; CHF=congestive heart failure; CV=cardiovascular; DM=diabetes; EUROPA=EURopean trial On reduction of cardiac events with
Perindopril with stable coronary Artery disease; HOPE=Heart Outcomes Prevention Evaluation; MI=myocardial infarction; NS=nonsignificant; PVD=peripheral vascular disease;
PROGRESS=Perindopril pROtection aGainst REcurrent Stroke Study; TIA=transient ischemic attack.
aThe PROGRESS and EUROPA trials defined hypertension as BPX160/90 mmHg; the CAMELOT defined hypertension as DBPX100 mmHg. However, mean BP in PROGRESS
and CAMELOT were 136/79 mmHg and 129/78 mmHg, respectively. In EUROPA, the BP for the entire cohort (both hypertensive and normotensive) was 137/82 mmHg –
presumably the normotensive group had a lower mean entry BP.
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absolute risk of cardiovascular outcomes is high, such as
diabetes,45,49,50 coronary artery disease,46,49,51 and cerebro-
vascular disease,52 a requirement necessary to achieve
adequate statistical power during the relatively short duration
of a randomized trial.
Type II diabetics with baseline blood pressures o140/
80 mmHg were randomized in the normotensive ABCD
(Appropriate Blood pressure Control in Diabetes) trial to
placebo or active treatment with either enalapril or
nisoldipine.45 During five years of follow-up, the incidence
of strokes was 70% lower in the active treatment group
(P¼ 0.03) compared to the placebo group (mean BP 137/
81 mmHg compared to 128/75 mmHg in the active treatment
group).45 Among a subset of these patients with peripheral
vascular disease in addition to diabetes, the aggressive
blood pressure treatment also reduced the risk of a combined
cardiovascular end point of CV death, nonfatal stroke,
and nonfatal myocardial infarction by approximately
two-thirds.50 Treatment of ‘normotensive’ diabetics with
ramipril in the HOPE (Heart Outcomes Prevention Evalua-
tion) study also resulted in a reduction of cardiovascular
events.49
The CAMELOT (Comparison of AMlodipine vs. Enalapril
to Limit Outcomes of Thrombosis) study randomized 1991
individuals with angiographically confirmed coronary artery
CAMELOT vs. Endapril to Limit Outcomes of Thrombosi
(disease and a mean baseline blood pressure of 129/78 mmHg
to either placebo or active treatment (10 mg of amlodipine or
20 mg of enalapril).46 Active treatment resulted in a blood
pressure separation from placebo of about 5/2.5 mmHg.
During 2 years of follow-up, the occurrence of the
cardiovascular end point was reduced by 30% with
amlodipine therapy. Enalapril therapy lowered the risk by
20%, but this was not statistically significant. Among
participants with known coronary artery disease in the
EUROPA (EURopean trial On reduction of cardiac events
with Perindopril with stable coronary Artery disease) study,
active treatment led to a 20% lower cardiovascular event
rate, along with an average 5/2 mmHg reduction in blood
pressure compared to placebo; the results were consistent
whether participants were ‘hypertensive’ or ‘normotensive’
at baseline.51
The PROGRESS (Perindopril pROtection aGainst REcur-
rent Stroke) Study included 3189 ‘normotensive’ participants
with a prior stroke history and mean entry blood pressure at
baseline of 136/79 mmHg.52 They were randomized to either
perindopril (resulting in a 5/3 mmHg fall in blood pressure),
a combination of perindopril and indapamide (resulting in a
12/5 mmHg fall in blood pressure), or placebo. All vascular
events were reduced by 24% with active therapy in this
‘normotensive’ group. However, combination therapy, con-
comitant with its greater effect on blood pressure, appeared
more effective: combination therapy reduced the risk of
recurrent stroke by 42% in these individuals.
Participants of the HOPE study had known cardiovascular
disease or diabetes at baseline, and 53% had blood pressures
o140/90 mmHg at entry.49 Blood pressure separation with
ramipril compared to placebo was 3/2 mmHg at the four
study visits, but in fact may have been more substantial given
the results of a substudy that measured ambulatory blood
pressure.53 Among the ‘normotensive’ group, the combined
cardiovascular end point was reduced by 20% with active
treatment.
Whether targeting a lower blood pressure goal of o130/
80 mmHg compared to o140/90 mmHg reduces the risk of
cardiovascular outcomes in another high-risk population,
namely those with nondiabetic chronic kidney disease,
remains undetermined. So far, three randomized trials have
examined this question.54–56 Although two did not show a
significant benefit to lower targets within the normal range,
the study with the longest follow-up and highest degree of
statistical power demonstrated a significant reduction in both
end-stage renal disease and all-cause mortality.56 The MDRD
(Modification of Diet in Renal Disease) Study achieved
a blood pressure separation of approximately 8/3 mmHg
(126/77 vs 134/80 mmHg) over 2 years; during an average of
6 years of follow-up, end-stage renal disease and all-cause
death was reduced by 23% in the group with lower blood
pressure.56
Thus, the current evidence provides us with both the
observation that the risk of cardiovascular events follows a
linear relationship with blood pressure and with the clinical
trial experimentation that achieving further blood pressures
reductions within the so-called ‘normal’ range indeed reduces
the risk of cardiovascular events.
Albuminuria-associated disease
‘Microalbuminuria’ is another term that should now be
eliminated from our lexicon, as there are ample data to
suggest that albuminuria in the ‘normal’ range carries
significant risk of vascular events.
The misconception of normoalbuminuria
Any degree of non-negligible albuminuria bears a significant
risk for cardiovascular events. Post hoc analyses of rando-
mized trials in high-risk individuals as well as community-
based cohort studies all indicate that incremental increases
in albuminuria within the ‘normal’ range carry higher
risks of cardiovascular morbidity and mortality, elevations
in blood pressure, and even noncardiovascular death
(Table 2).57–65 Moreover, data from the Steno Diabetes
Center in type I diabetics, as well as post hoc analyses of
RENAAL (Reduction of Endpoints in NIDDM with the
Angiotensin II Antagonist Losartan) data in patients
with type II diabetes, LIFE (Losartan Intervention For
Endpoint) reduction in hypertension data in patients with
‘hypertension’, and African American Study of Kidney
Disease and Hypertension data in African Americans with
nondiabetic chronic kidney disease all suggest that the degree
of albuminuria reduction in response to treatment is a
primary determinant of both renal and cardiovascular
outcomes.66–70
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Similar to cholesterol and blood pressure, there is a
continuous relationship between the level of albumin
excretion and the risk of cardiovascular events. The studies
outlined in Table 2, especially the data from HOPE, LIFE,
and Framingham, clearly suggest that only negligible
amounts of albuminuria should be considered normal.
Specifically, levels above approximately 2 mg/g of creatinine
(or an estimated excretion rate of 2 mg/day) are significantly
associated with cardiovascular death, myocardial infraction,
stroke, and elevation in blood pressure.57,58,63 The HOPE and
LIFE results further suggest that this association applies to
both diabetics and nondiabetics alike.57,58
Although no randomized trials have specifically addressed
the question of whether a reduction in albuminuria would
result in a concomitant reduction in renal and cardiovascular
events, multiple observations suggest this may be true.
Parving and colleagues showed that the degree of albuminur-
ia reduction during the first year of therapy was the best
predictor of slowing progression of renal disease in type I
diabetics.55,56 Among type II diabetics, the RENAAL
investigators took advantage of a 6-month on-treatment
re-evaluation of risk factors to determine if a decrease in
albuminuria was associated with a favorable outcome.68 After
adjustment for multiple risk factors, a 30% or greater
decrement in albumin excretion at 6 months was associated
with a 35% reduction in the combined cardiovascular end
point independent of the concomitant 6-month change in
blood pressure, renal function, body size, or hemoglobin A1c.
Table 2 | Risk of cardiovascular events associated with albuminuria within the ‘normal’ range
Study Population Outcome Risk assessment
Post hoc analyses of randomized trials in high-risk individuals
HOPE Known vascular disease or
diabetes plus one other
CV risk factor
n=9043
Composite of CV death,
nonfatal stroke, nonfatal MI
Risk began to increase with excretion rates above
an albumin/creatinine ratio as low as 1.9 mg/g
Risk increased 6% for every 4 mg/g increment
LIFE Hypertension and LVH
n=8206
Composite of CV death,
nonfatal stroke, nonfatal MI
Risk began to increase with excretion rates above
an albumin/creatinine ratio as low as 2.2 mg/g (for
e.g., 60% increased risk associated with 14–22 mg/g
compared to o2.2 mg/g
Risk increased 55% for every 10-fold increment
Community-based cohort studies
PREVENDa Community residing adults in
Groningen, The Netherlands
n=40 548
CV death
Non-CV death
Risk of CV death increased 29% for every twofold
increase in urine albumin concentration (on early
morning sample)
Risk of non-CV death increased 12% for every
twofold increase in urine albumin concentration
Copenhagen
Community
Cohort
Community residing older
adults (aged 50–89 yr)
without prevalent heart or
renal failure
n=626
Composite of CV death, MI,
stroke, TIA, unstable angina,
CHF
Risk was 2.3-fold higher among those with
albumin/creatinine ratio 418.4 mg/g compared to
those p18.4 mg/g
Copenhagen City
Heart Study
Individuals without prior CHD
drawn from community residing
adults in Copenhagen
n=2762
CHD and death Compared to p6.9 mg/24 h, an albumin excretion
46.9 mg/24 h carried a twofold increased risk, and
421 mg/24 h carried a 2.2-fold increased risk
Framingham Heart
Study Offspring
Community residing adults
without hypertension or
diabetes
n=1499
New-onset hypertension
Increase in JNC-7 BP category
Risk of increased blood pressure was higher with
increasing albumin/creatinine ratios using
p1.7 mg/g as the comparison group; for example,
an albumin/creatinine ratio 1.7–3.8 mg/g was
associated with a 90% increase in risk of developing
hypertension
Framingham Heart
Study Offspring
Community residing adults
without hypertension or
diabetes
n=1568
Composite of CV death, MI,
stroke, TIA, angina, CHF,
or claudication
An albumin excretion X3.9 mg/g in men and
X7.5 mg/g in women was associated with a
threefold higher risk of incident CVD events
Nord-Trondelag
Health Study
Community residing adults in
Nord-Trondelag, Norway
without baseline
hypertension, diabetes,
or CVD
n=1989
Death An albumin excretion X6.7 mg/g was associated
with a 2.3-fold increased risk of death
CHF=congestive heart failure; CHD=coronary heart disease; CV=cardiovascular; HOPE=Heart Outcomes Prevention Evaluation; LIFE=Losartan Intervention For Endpoint
reduction in hypertension; MI=myocardial infarction; PREVEND=Prevention of Renal and Vascular ENd-stage Disease; TIA=transient ischemic attack.
aThe PREVEND study did not normalize albumin excretions to creatinine.
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In fact, among all risk-factor changes between baseline and 6
months, only persistent albuminuria was significantly pre-
dictive of cardiovascular events. Expressed as a continuous
variable, every halving of albumin excretion was associated
with an 18% lower risk of cardiovascular events. In a post hoc
analysis of nondiabetics with kidney disease, the African
American Study of Kidney Disease and Hypertension investi-
gators examined whether 6-month on-treatment change in
albuminuria predicted end-stage renal disease.70 After adjust-
ment for treatment arm and baseline albuminuria, a 20–50%
reduction in albumin excretion at 6-months was asso-
ciated with an approximate 50% lower risk of end-stage renal
disease, and if albuminuria was lowered by more than half, the
relative risk of end-stage renal disease was cut by almost 75%.
As with blood pressure, the available evidence argues that
cardiovascular risk follows a continuous positive relationship
with albumin excretion and that lowering albuminuria
independently lowers the risk of renal and cardiovascular
events.
WHAT IS NORMAL? A CENTRAL QUESTION WITH BROADER
APPLICATION
The main thrust of this argument is that our current
definitions of ‘normal’ for blood pressure and albuminuria
are, in fact, abnormal, and that the terminology ‘hyper-
tension’ and ‘microalbuminuria’ are misleading in suggesting
dichotomy where associations are continuous. Observational
data show that for both blood pressure and albuminuria,
lower is clearly better in both high- and usual-risk
individuals, whereas randomized trials illustrate benefit in
treating high-risk individuals with ‘normal’ levels of blood
pressure.
Because unguided pharmacotherapy is neither prudent
nor feasible for clinicians and patients, and the risks of
therapy must temper the absolute (rather than relative)
benefits – which obviously differ by an individual’s baseline
risk of cardiovascular disease – the maintenance of guidelines
employing categories of blood pressure and albuminuria is
likely inevitable. Nevertheless, given that ‘normal’ is not
normal, we urge that future randomized trials identify levels
of blood pressure and albuminuria, below which further
therapy is no longer beneficial.
In addition, we believe that our central question, ‘what
is normal’, has broader applicability in clinical medicine, and
should spark re-evaluation of ‘normal’ among a variety
of parameters. For example, are risks associated with a fasting
plasma glucose of 90 mg/dl the same as those associated
with 125 mg/dl? Should the term ‘impaired glucose tolerance’
be re-evaluated? A body mass index of 24.9 imparts greater
risk than a body mass index of 20 kg/m2; should the arbitrary
definition of ‘normal’ weight be changed? Many other
examples probably exist. During the course of human
history, our behavior and environment fell out of step
from our genetic heritage, explaining the clinical benefits
observed with closer proximity to paleo- rather than neo-
normality.
REFERENCES
1. Report of the Joint National Committee on Detection, Evaluation, and
Treatment of High Blood Pressure. A cooperative study. JAMA 1977; 237:
255–261.
2. The 1980 Report of the Joint National Committee on Detection,
Evaluation, and Treatment of High Blood Pressure. Arch Intern Med
1980; 140: 1280–1285.
3. The 1984 Report of the Joint National Committee on Detection,
Evaluation, and Treatment of High Blood Pressure. Arch Intern Med
1984; 144: 1045–1057.
4. The 1988 Report of the Joint National Committee on Detection,
Evaluation, and Treatment of High Blood Pressure. Arch Intern Med
1988; 148: 1023–1038.
5. The Fifth Report of the Joint National Committee on Detection,
Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern
Med 1993; 153: 154–183.
6. The Sixth Report of the Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern
Med 1997; 157: 2413–2446.
7. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint
National Committee on Prevention, Detection, Evaluation, and Treatment
of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560–2572.
8. Wang Y, Wang QJ. The prevalence of prehypertension and hypertension
among US adults according to the new joint national committee
guidelines: new challenges of the old problem. Arch Intern Med 2004;
164: 2126–2134.
9. Viberti G, Pickup JC, Bilous RW et al. Correction of exercise-induced
microalbuminuria in insulin-dependent diabetics after 3 weeks of
subcutaneous insulin infusion. Diabetes 1981; 30: 818–823.
10. Viberti GC, Hill RD, Jarrett RJ et al. Microalbuminuria as a predictor of
clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982;
1: 1430–1432.
11. Svendsen PA, Oxenboll B, Christiansen JS. Microalbuminuria in diabetic
patients – a longitudinal study. Acta Endocrinol Suppl (Copenhagen) 1981;
242: 53–54.
12. Mathiesen ER, Ronn B, Jensen T et al. Relationship between
blood pressure and urinary albumin excretion in development of
microalbuminuria. Diabetes 1990; 39: 245–249.
13. Morwood MJ, Brown P, Jatmiko et al. Further evidence for small-bodied
hominins from the Late Pleistocene of Flores, Indonesia. Nature 2005;
437: 1012–1017.
14. Oliver WJ, Cohen EL, Neel JV. Blood pressure, sodium intake, and sodium
related hormones in the Yanomamo Indians, a ‘no-salt’ culture.
Circulation 1975; 52: 146–151.
15. Lowenstein FM. A study of blood pressure and body measurements in
medical students in the Brazilian Amazon City Belem. Cardiologia 1961;
39: 46–56.
16. Whyte HM, Yee IL. Serum cholesterol levels of Australians and natives of
New Guinea from birth to adulthood. Australas Ann Med 1958; 7: 336–339.
17. Whyte HM, Graham IA, De Wolfe MS. Body fat, blood pressure and serum
cholesterol of Australian men. Australas Ann Med 1958; 7: 328–335.
18. De Wolfe MS, Whyte HM. Serum cholesterol and lipoproteins in natives of
New Guinea and Australians. Australas Ann Med 1958; 7: 47–54.
19. Whyte HM. Body fat and blood pressure of natives in New Guinea:
reflections on essential hypertension. Australas Ann Med 1958; 7: 36–46.
20. Casley-Smith JR. Blood pressures in Australian aborigines. Med J Aust
1959; 46: 627–633.
21. Maddocks I. Blood pressures in Melanesians. Med J Aust 1967; 1: 1123–1126.
22. Fleming-Moran M, Santos RV, Coimbra Junior CE. Blood pressure levels of
the Surui and Zoro Indians of the Brazilian Amazon: group- and
sex-specific effects resulting from body composition, health status,
and age. Hum Biol 1991; 63: 835–861.
23. Ghesquiere JL, Karvonen MJ. Some anthropometric and functional
dimensions of the pygmy (Kivu Twa). Ann Hum Biol 1981; 8: 119–134.
24. Hollenberg NK, Martinez G, McCullough M et al. Aging, acculturation, salt
intake, and hypertension in the Kuna of Panama. Hypertension 1997; 29:
171–176.
25. Diamond JM. Human evolution. Diabetes running wild. Nature 1992; 357:
362–363.
26. Sharma AM. The thrifty-genotype hypothesis and its implications for the
study of complex genetic disorders in man. J Mol Med 1998; 76: 568–571.
27. James G, Baker P. Human Population Biology and Blood Pressure:
Evolutional and Ecological Considerations and Interpretations of Population
Studies, 2nd edn. Raven Press: New York, 1995.
28. Page LB. Epidemiologic evidence on the etiology of human hypertension
and its possible prevention. Am Heart J 1976; 91: 527–534.
Kidney International (2006) 69, 22–28 27
JP Forman and BM Brenner: Hypertension and microalbuminuria m i n i r e v i e w
29. Hollenberg NK, Martinez G, McCullough M et al. Aging, acculturation, salt
intake, and hypertension in the Kuna of Panama. Hypertension 1997; 29:
171–176.
30. Executive Summary of The Third Report of the National Cholesterol
Education Program (NCEP) Expert Panel on Detection, Evaluation, and
Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
JAMA 2001; 285: 2486–2497.
31. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials
for the National Cholesterol Education Program Adult Treatment Panel III
guidelines. Arterioscler Thromb Vasc Biol 2004; 24: e149–e161.
32. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low
density lipoprotein cholesterol, ischaemic heart disease, and stroke:
systematic review and meta-analysis. BMJ 2003; 326: 1423.
33. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin
in 20 536 high-risk individuals: a randomised placebo-controlled trial.
Lancet 2002; 360: 7–22.
34. Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate
lipid lowering with statins after acute coronary syndromes. N Engl J Med
2004; 350: 1495–1504.
35. Rose G. Sick individuals and sick populations. Int J Epidemiol 2001; 30:
427–432 (discussion 433–424).
36. MacMahon S, Neal B, Rodgers A. Hypertension – time to move on.
Lancet 2005; 365: 1108–1109.
37. Anderson TW. Re-examination of some of the Framingham
blood-pressure data. Lancet 1978; 2: 1139–1141.
38. Stewart IM. Relation of reduction in pressure to first myocardial infarction
in patients receiving treatment for severe hypertension. Lancet 1979; 1:
861–865.
39. Untreated mild hypertension. A Report by the Management Committee
of the Australian Therapeutic Trial in Mild Hypertension. Lancet 1982; 1:
185–191.
40. Cooper SP, Hardy RJ, Labarthe DR et al. The relation between degree of
blood pressure reduction and mortality among hypertensives in the
Hypertension Detection and Follow-Up Program. Am J Epidemiol 1988;
127: 387–403.
41. Jafar TH, Stark PC, Schmid CH et al. Progression of chronic kidney
disease: the role of blood pressure control, proteinuria, and
angiotensin-converting enzyme inhibition: a patient-level
meta-analysis. Ann Intern Med 2003; 139: 244–252.
42. Berl T, Hunsicker LG, Lewis JB et al. Impact of achieved blood pressure on
cardiovascular outcomes in the irbesartan diabetic nephropathy trial.
J Am Soc Nephrol 2005; 16: 2170–2179.
43. Kannel WB, Wilson PW, Nam BH et al. A likely explanation for the J-curve
of blood pressure cardiovascular risk. Am J Cardiol 2004; 94: 380–384.
44. SHEP Cooperative Research Group. Prevention of stroke by
antihypertensive drug treatment in older persons with isolated systolic
hypertension. Final results of the Systolic Hypertension in the Elderly
Program (SHEP). JAMA 1991; 265: 3255–3264.
45. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood
pressure control in normotensive type 2 diabetic patients on albuminuria,
retinopathy and strokes. Kidney Int 2002; 61: 1086–1097.
46. Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensive agents on
cardiovascular events in patients with coronary disease and normal blood
pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004;
292: 2217–2225.
47. Lewington S, Clarke R, Qizilbash N et al. Age-specific relevance of usual
blood pressure to vascular mortality: a meta-analysis of individual data
for one million adults in 61 prospective studies. Lancet 2002; 360:
1903–1913.
48. MacMahon S, Peto R, Cutler J et al. Blood pressure, stroke, and coronary
heart disease. Part 1. Prolonged differences in blood pressure:
prospective observational studies corrected for the regression dilution
bias. Lancet 1990; 335: 765–774.
49. Yusuf S, Sleight P, Pogue J et al. Effects of an
angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular
events in high-risk patients. The Heart Outcomes Prevention Evaluation
Study Investigators. N Engl J Med 2000; 342: 145–153.
50. Mehler PS, Coll JR, Estacio R et al. Intensive blood pressure control
reduces the risk of cardiovascular events in patients with peripheral
arterial disease and type 2 diabetes. Circulation 2003; 107: 753–756.
51. Fox KM. Efficacy of perindopril in reduction of cardiovascular events
among patients with stable coronary artery disease: randomised,
double-blind, placebo-controlled, multicentre trial (the EUROPA study).
Lancet 2003; 362: 782–788.
52. Randomised trial of a perindopril-based blood-pressure-lowering
regimen among 6105 individuals with previous stroke or transient
ischaemic attack. Lancet 2001; 358: 1033–1041.
53. Svensson P, de Faire U, Sleight P et al. Comparative effects of ramipril on
ambulatory and office blood pressures: a HOPE substudy. Hypertension
2001; 38: E28–E32.
54. Wright Jr JT, Bakris G, Greene T et al. Effect of blood pressure lowering
and antihypertensive drug class on progression of hypertensive kidney
disease: results from the AASK trial. JAMA 2002; 288: 2421–2431.
55. Ruggenenti P, Perna A, Loriga G et al. Blood-pressure control for
renoprotection in patients with non-diabetic chronic renal disease
(REIN-2): multicentre, randomised controlled trial. Lancet 2005; 365:
939–946.
56. Sarnak MJ, Greene T, Wang X et al. The effect of a lower target blood
pressure on the progression of kidney disease: long-term follow-up of the
modification of diet in renal disease study. Ann Intern Med 2005; 142:
342–351.
57. Gerstein HC, Mann JF, Yi Q et al. Albuminuria and risk of cardiovascular
events, death, and heart failure in diabetic and nondiabetic individuals.
JAMA 2001; 286: 421–426.
58. Wachtell K, Ibsen H, Olsen MH et al. Albuminuria and cardiovascular risk
in hypertensive patients with left ventricular hypertrophy: the LIFE study.
Ann Intern Med 2003; 139: 901–906.
59. Hillege HL, Fidler V, Diercks GF et al. Urinary albumin excretion predicts
cardiovascular and noncardiovascular mortality in general population.
Circulation 2002; 106: 1777–1782.
60. Kistorp C, Raymond I, Pedersen F et al. N-terminal pro-brain natriuretic
peptide, C-reactive protein, and urinary albumin levels as predictors of
mortality and cardiovascular events in older adults. JAMA 2005; 293:
1609–1616.
61. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B et al. Very low levels of
microalbuminuria are associated with increased risk of coronary heart
disease and death independently of renal function, hypertension, and
diabetes. Circulation 2004; 110: 32–35.
62. Klausen KP, Scharling H, Jensen G, Jensen JS. New definition of
microalbuminuria in hypertensive subjects: association with incident
coronary heart disease and death. Hypertension 2005; 46: 1–5.
63. Wang TJ, Evans JC, Meigs JB et al. Low-grade albuminuria and the risks of
hypertension and blood pressure progression. Circulation 2005; 111:
1370–1376.
64. Arnlov J, Evans JC, Meigs JB et al. Low-grade albuminuria and incidence
of cardiovascular disease events in nonhypertensive and nondiabetic
individuals: the Framingham Heart Study. Circulation 2005; 112:
969–975.
65. Romundstad S, Holmen J, Kvenild K et al. Microalbuminuria and all-cause
mortality in 2089 apparently healthy individuals: a 4.4-year follow-up
study. The Nord-Trondelag Health Study (HUNT), Norway. Am J Kidney Dis
2003; 42: 466–473.
66. Rossing P, Hommel E, Smidt UM, Parving HH. Reduction in albuminuria
predicts diminished progression in diabetic nephropathy. Kidney Int Suppl
1994; 45: S145–S149.
67. Rossing P, Hommel E, Smidt UM, Parving HH. Reduction in albuminuria
predicts a beneficial effect on diminishing the progression of human
diabetic nephropathy during antihypertensive treatment. Diabetologia
1994; 37: 511–516.
68. de Zeeuw D, Remuzzi G, Parving HH et al. Albuminuria, a therapeutic
target for cardiovascular protection in type 2 diabetic patients with
nephropathy. Circulation 2004; 110: 921–927.
69. Ibsen H, Olsen MH, Wachtell K et al. Reduction in albuminuria translates
to reduction in cardiovascular events in hypertensive patients: losartan
intervention for endpoint reduction in hypertension study. Hypertension
2005; 45: 198–202.
70. Lea J, Greene T, Hebert L et al. The relationship between magnitude of
proteinuria reduction and risk of end-stage renal disease: results of the
African American study of kidney disease and hypertension. Arch Intern
Med 2005; 165: 947–953.
28 Kidney International (2006) 69, 22–28
m i n i r e v i e w JP Forman and BM Brenner: Hypertension and microalbuminuria
